Liarozole dihydrochloride
Modify Date: 2024-01-10 14:48:40
Liarozole dihydrochloride structure
|
Common Name | Liarozole dihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1883548-96-6 | Molecular Weight | 381.69 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H15Cl3N4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Liarozole dihydrochlorideLiarozole dihydrochloride (R75251; R85246) is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase). Liarozole dihydrochloride prevents the catabolism of retinoic acid via inhibition of 4-hydroxylase and exhibits retinoid sparing and retinoid-mimetic effects in vivo. Liarozole dihydrochloride is an imidazole derivative; it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders[1]. |
| Name | Liarozole dihydrochloride |
|---|
| Description | Liarozole dihydrochloride (R75251; R85246) is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase). Liarozole dihydrochloride prevents the catabolism of retinoic acid via inhibition of 4-hydroxylase and exhibits retinoid sparing and retinoid-mimetic effects in vivo. Liarozole dihydrochloride is an imidazole derivative; it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Liarozole inhibits the metabolism of retinoic acid to more polar metabolites in hamster liver microsomes (IC50=2.2 μM), rat liver homogenate (IC50=0.14 μM), dunning prostate cancer homogenate (IC50=0.26 μM) and MCF-7 human breast cancer cells (almost complete block at 10μM) [1]. Liarozole inhibits 17a-hydroxylase activity in bovine adrenal microsomes (IC50=0.15 μM) [1]. Liarozole has modest inhibitory activity on cholesterol synthesis in human hepatoma cells(IC50=5 μM)[1]. |
| References |
[1]. Bryson HM, et al. Liarozole. Drugs Aging. 1996 Dec;9(6):478-84; discussion 485. |
| Molecular Formula | C17H15Cl3N4 |
|---|---|
| Molecular Weight | 381.69 |
| Storage condition | -20°C |